Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announces that it has completed its acquisition of LumiThera, Inc., a leader in light-based innovations for ophthalmology. The acquisition includes the noninvasive Valeda® photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD), and a sub-set of late dry AMD (non-central involving geographic atrophy). Valeda PBM is currently available in the U.S., and several countries in Europe and Latin America.
Read the full article: Alcon Completes Acquisition of LumiThera //
Source: https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Completes-Acquisition-of-LumiThera/default.aspx